Key features
Customizable serotype-specific detection
The assay is a 96-well ELISA tailored to wild-type and novel capsid variants, including engineered or chimeric AAVs. This customization ensures accurate profiling of capsid-specific immune responses.
High sensitivity to complement activation
Detects complement activation products deposited in the assay as a result of AAV-triggered complement activation. This detection has been demonstrated even at low antibody titers, reflecting real-world patient variability.
A mechanistic insight
Captures pathway-independent complement activation, mitigating the uncertainties in AAV-mediated immunogenicity and risk of false negatives.
1. ELISA plate coated with immobilized vector
Wild-type vectors or your custom vector can be used.
2. Capture of Anti-AAV Binders
Anti-AAV antibodies and potential complement activators (e.g., immunoglobulins/C1q, MBL/ficolins, and C3b) are captured from a human serum sample under complement-suppressing conditions.
3. Complement activation
Following a washing step, the serum sample is reapplied in a complement-permissive buffer. If complement-activating binders are present, terminal pathway activity results in TCC deposition.
4. Detection
Detection is performed using an anti-TCC antibody, generating a signal proportional to the level of complement activation.